QASIM ALKHAFAF: Open Payments
NPI 1861951014 · SOUTHFIELD, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,005 in 61 payments from 11 companies in 2025. Trend: 2023 $284 · 2024 $552 · 2025 $1,005
Food & beverage: $1,005
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $153 |
| Janssen Pharmaceuticals, Inc | 12 | $147 |
| ABBVIE INC. | 6 | $135 |
| Teva Pharmaceuticals USA, Inc. | 6 | $101 |
| Alkermes, Inc. | 4 | $98 |
| E.R. Squibb & Sons, L.L.C. | 5 | $95 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Noven Therapeutics, LLC | 1 | $25 |
Products named: CAPLYTA, INVEGA SUSTENNA, VRAYLAR, COBENFY, ABILIFY ASIMTUFII, UZEDY, ARISTADA, REXULTI.
Industry payments across MI — which companies pay providers there.
